Specialty Pharmacy

Top news of the day from across the health care landscape.

Baricitinib significantly improved patient-reported outcomes in individuals with RA.

New drugs for psoriatic arthritis discussed during a session at the ACR/ARHP conference.

At the Annual Meeting of the American College of Rheumatology in Washington, DC, several experts presented their progress in harnessing technology to help teenagers and young adults manage their juvenile arthritis.

Study compares the safety and efficacy of sarilumab with adalimumab in patients who cannot tolerate methotrexate.

Wayne Grau, vice president of Legislative Affairs at Managed Health Care Associates, discusses the implications of the Medicare Home Infusion Site of Care Act for specialty pharmacy stakeholders.

Reduced reimbursements, Medicare Part D, and the Affordable Care Act have stimulated pharmacies to offer a broader palette of services.

Combination immunotherapy more successful in treating advanced skin cancer.

An ACR session focused on the Sunshine Act and health care transparency.

Baricitinib is a once-daily oral selective JAK1 and JAK2 inhibitor for the treatment of autoimmune and inflammatory diseases.

Two pilot studies are transplanting infected kidneys into patients and then treating them with curative hepatitis C medications.

Sarilumab shows promise on circulating biomarkers of bone and joint destruction in patients with rheumatoid arthritis who had shown an inadequate response to methotrexate.

Patients with rheumatoid arthritis who demonstrate a less-than-adequate response to a tumor necrosis factor inhibitor can be treated with another disease-modifying antirheumatic drug.

Regulatory perspectives presented at ACR on biosimilars entering the market convey the importance of crafting antibodies to our own purposes.

Low health literacy, financial instability, and lack of social support promote poor adherence.

Top news of the day from across the health care landscape.

Zepatier shows promise across genotypes 1 and 4, even among patients administered opioid agonist therapy.

Stacey Ness, PharmD, RPh, CSP, MSCS, AAHIVP, senior director of Specialty Clinical Services at Managed Health Care Associates, discusses how specialty stakeholders will need to alter current patient management programs as new drugs transform the treatment of diseases into more manageable conditions.

New guidelines for rheumatoid arthritis treatment discussed at ACR conference.

Broadly neutralizing antibody delays viral rebound and opens doors for future HIV vaccines.

ACR session reinforces the need for new research about how the genome, epigenome, and other factors play a role in rheumatoid arthritis.

CD98 molecule could be a potential therapeutic target in AML.

Comparing healthy and cancerous cells from the same individual could allow for a better understanding of translocations involved.

There is building consensus that multiple sclerosis and rheumatoid arthritis display similar autoimmune genetic pathways.

Vemlidy treats patients with chronic hepatitis B infection with compensated liver disease.

Top news of the day from across the health care landscape.

National Association of Specialty Pharmacy emphasizes work with manufacturers, prescribers and payers to ensure the availability of specialty medications and services that ensure optimal patient outcomes.

Specialty pharmacies must be prepared to innovate as biosimilars hit the US market.

Opdivo is approved for metastatic melanoma, non-small cell lung cancer, renal cell carcinoma, and classical Hodgkin lymphoma.

Gilenya may cause an increase in CD56+-expressing T cells, which can cause MS relapse.